CANY
VRNA

Caxton Associates (New York)’s Verona Pharma VRNA Stock Holding History

Caxton Associates (New York)’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$1.37M Buy
+29,552
New +$1.11M 0.04% 163

Other funds holding VRNA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Caxton Associates (New York)'s VRNA Position: Q4 2024 in Review

Caxton Associates (New York) opened a new position in Verona Pharma (VRNA) in Q4 2024: 29,552 shares worth $1.37M. The stake represents 0.04% of the portfolio and ranks #163 among its holdings.

191 funds tracked by Wall St. Rank hold VRNA as of Q4 2024.

  • Caxton Associates (New York) held 29,552 shares of Verona Pharma worth $1.37M as of Q4 2024.
  • Verona Pharma was a new Caxton Associates (New York) position in Q4 2024.
  • Verona Pharma made up 0.04% of Caxton Associates (New York)'s portfolio in Q4 2024, its #163 holding.
  • 191 funds tracked by Wall St. Rank held Verona Pharma as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.